Glifozins in the treatment of type 2 diabetes: beyond the benefits in metabolic control

Abstract

Introduction: Gliflozins are a group of drugs that were initially developed for the management of diabetes mellitus due to their hypoglycemic functions. However, recent research reports benefits against cardiovascular comorbidities. Objective: To describe the usefulness of glyphozins in the treatment of Type 2 Diabetes, not only for its benefits in metabolic control, but also for its therapeutic scope in reducing cardiorenal risk. Methodology: A search was carried out in Spanish and English in different databases such as Pubmed, ScienceDirect, Redalyc, and SciELO, with the descriptors Gliflozins, Type 2 Diabetes Mellitus and Cardiometabolic Risk using the Boolean AND and OR, finding 78 publications and selecting 15 .Results: Benefits were observed beyond reducing glycemia values ​​with an important cardionephroprotective effect on atherosclerosis, heart failure, cardiovascular mortality and progression to kidney disease. Conclusions: The identification of these benefits in patients and their consequent impact on improving living conditions and reducing cardiovascular risk are valuable enough to be considered as part of the therapies to be provided by health services public and private